# Treatment of Metastatic Melanoma With Tumor Infiltrating Lymphocytes and IL-2 Following Lympho-depleting Chemotherapy

> **NCT00604136** · PHASE2 · UNKNOWN · sponsor: **Hadassah Medical Organization** · enrollment: 20 (estimated)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **BIOLOGICAL:** tumor infiltrating lymphocytes

## Key facts

- **NCT ID:** NCT00604136
- **Lead sponsor:** Hadassah Medical Organization
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-07
- **Primary completion:** 2019-12
- **Final completion:** 2020-07
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2018-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00604136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00604136, "Treatment of Metastatic Melanoma With Tumor Infiltrating Lymphocytes and IL-2 Following Lympho-depleting Chemotherapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00604136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*